We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN - Free Report) and Sanofi (SNY - Free Report) published detailed data from their joint late-stage study MELODY, which is evaluating a single dose of their respiratory syncytial virus (RSV) vaccine candidate nirsevimab for protection of infants.
Data from the study demonstrated that the study met its primary endpoint of reducing the incidence of medically-attended lower respiratory tract infections (LRTI). A single dose of AstraZeneca and Sanofi’s nirsevimab reduced LRTI like bronchiolitis or pneumonia caused by RSV 74.5% compared to placebo in infants born at term or late preterm.
Another phase II/III study MEDLEY is evaluating nirsevimab in preterm infants and infants with congenital heart disease (CHD) and chronic lung disease (CLD) entering the first RSV season. Data from this study demonstrated that the vaccine candidate has a safety and tolerability profile similar to the only available preventative option for RSV, which is Synagis. Serum levels in the MEDLEY study were same as the levels achieved in the MELODY study. It implies similar protection for preterm infants, and infants with CHD and CLD compared to those born at term or late preterm.
Data from a pre-specified pooled analysis of phase III and phase II studies shows that nirsevimab achieved an efficacy of 77.3% in term and preterm infants against RSV-associated hospitalizations.
AstraZeneca and Sanofi are developing the vaccine candidate under a collaboration agreement. The European regulatory submission of AstraZeneca and Sanofi’s nirsevimab vaccine was accepted under accelerated assessment for RSV protection in all infants last month.
Shares of AstraZeneca and Sanofi have gained 38.7% and 14%, respectively, in the past year compared with the industry’s rise of 18.4%.
Image Source: Zacks Investment Research
RSV is a common and pervasive cause of acute respiratory illness, which usually starts in the fall months. This highly contagious virus affects the lungs and airways.
Some other companies are also developing their respective vaccines for treating RSV.
Earlier this week, the FDA granted a Breakthrough Therapy designation to Pfizer’s (PFE - Free Report) RSV vaccine candidate RSVpreF. PFE is developing the vaccine candidate as an active immunization of pregnant women to prevent RSV-associated LRTI in infants as well as for immunizing older adults.
Pfizer is currently conducting multiple late-stage studies on RSVpreF.
British pharma giant Glaxo (GSK - Free Report) is evaluating its maternal RSV vaccine candidate in the phase III GRACE study. The study is evaluating the efficacy of a single dose of the unadjuvanted candidate in pregnant women.
Glaxo is also developing RSV vaccines for pediatric patients and older adults using different novel technologies.
Image: Bigstock
AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections
AstraZeneca (AZN - Free Report) and Sanofi (SNY - Free Report) published detailed data from their joint late-stage study MELODY, which is evaluating a single dose of their respiratory syncytial virus (RSV) vaccine candidate nirsevimab for protection of infants.
Data from the study demonstrated that the study met its primary endpoint of reducing the incidence of medically-attended lower respiratory tract infections (LRTI). A single dose of AstraZeneca and Sanofi’s nirsevimab reduced LRTI like bronchiolitis or pneumonia caused by RSV 74.5% compared to placebo in infants born at term or late preterm.
Another phase II/III study MEDLEY is evaluating nirsevimab in preterm infants and infants with congenital heart disease (CHD) and chronic lung disease (CLD) entering the first RSV season. Data from this study demonstrated that the vaccine candidate has a safety and tolerability profile similar to the only available preventative option for RSV, which is Synagis. Serum levels in the MEDLEY study were same as the levels achieved in the MELODY study. It implies similar protection for preterm infants, and infants with CHD and CLD compared to those born at term or late preterm.
Data from a pre-specified pooled analysis of phase III and phase II studies shows that nirsevimab achieved an efficacy of 77.3% in term and preterm infants against RSV-associated hospitalizations.
AstraZeneca and Sanofi are developing the vaccine candidate under a collaboration agreement. The European regulatory submission of AstraZeneca and Sanofi’s nirsevimab vaccine was accepted under accelerated assessment for RSV protection in all infants last month.
Shares of AstraZeneca and Sanofi have gained 38.7% and 14%, respectively, in the past year compared with the industry’s rise of 18.4%.
Image Source: Zacks Investment Research
RSV is a common and pervasive cause of acute respiratory illness, which usually starts in the fall months. This highly contagious virus affects the lungs and airways.
Some other companies are also developing their respective vaccines for treating RSV.
Earlier this week, the FDA granted a Breakthrough Therapy designation to Pfizer’s (PFE - Free Report) RSV vaccine candidate RSVpreF. PFE is developing the vaccine candidate as an active immunization of pregnant women to prevent RSV-associated LRTI in infants as well as for immunizing older adults.
Pfizer is currently conducting multiple late-stage studies on RSVpreF.
British pharma giant Glaxo (GSK - Free Report) is evaluating its maternal RSV vaccine candidate in the phase III GRACE study. The study is evaluating the efficacy of a single dose of the unadjuvanted candidate in pregnant women.
Glaxo is also developing RSV vaccines for pediatric patients and older adults using different novel technologies.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank
AstraZeneca and Sanofi currently carry a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.